Literature DB >> 277237

The effect of the radiosensitizer misonidazole on motor nerve conduction velocity in the mouse.

D G Hirst, B Vojnovic, I J Stratford, E L Travis.   

Abstract

The clinical use of misonidazole as a hypoxic cell radiosensitizer is at present limited by its neurotoxicity at high doses (Urtasun et al., 1977; Dische et al., 1977). An in vivo neurological end point, viz. measurement of nerve conduction velocity, has been developed to examine sensitizer action. Conduction velocity in mice was measured as a function of time after a single dose of misonidazole and as a function of drug dose. Doses greater than 0.33 mg/g produced significant transient reductions in velocity. The time course of the reduction in velocity closely followed the uptake/excretion profile of misonidazole from blood serum.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277237      PMCID: PMC2149369     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  6 in total

1.  Electrodiagnostic study of a patient with peripheral neuropathy after nitrofurantoin therapy.

Authors:  J C Honet
Journal:  Arch Phys Med Rehabil       Date:  1967-04       Impact factor: 3.966

2.  Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.

Authors:  G E Adams; I R Flockhart; C E Smithen; I J Stratford; P Wardman; M E Watts
Journal:  Radiat Res       Date:  1976-07       Impact factor: 2.841

3.  Metronidazole neuropathy.

Authors:  A Coxon; C A Pallis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-04       Impact factor: 10.154

4.  Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.

Authors:  R C Urtasun; P Band; J D Chapman; H R Rabin; A F Wilson; C G Fryer
Journal:  Radiology       Date:  1977-03       Impact factor: 11.105

5.  Mammalian cell toxicity of nitro compounds : dependence upon reduction potential.

Authors:  G E Adams; E D Clarke; R S Jacobs; I J Stratford; R G Wallace; P Wardman; M E Watts
Journal:  Biochem Biophys Res Commun       Date:  1976-10-04       Impact factor: 3.575

6.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

  6 in total
  7 in total

1.  Changes in nerve conduction velocity in the mouse after acute and chronic administration of nitroimidazoles.

Authors:  D G Hirst; B Vojnovic; B Hobson
Journal:  Br J Cancer       Date:  1979-02       Impact factor: 7.640

2.  Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes.

Authors:  Kyoung-In Cho; Dosuk Yoon; Sunny Qiu; Zachary Danziger; Warren M Grill; William C Wetsel; Paulo A Ferreira
Journal:  Dis Model Mech       Date:  2017-01-18       Impact factor: 5.758

3.  A biochemical method for assessing the neurotoxic effects of misonidazole in the rat.

Authors:  G P Rose; A J Dewar; I J Stratford
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

4.  Effect of acute and chronic misonidazole administration on peripheral-nerve electrophysiology in mice.

Authors:  P J Conroy; R Von Burg; D P Penney; W Passalacqua; R M Sutherland
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

5.  Misonidazole and MTDQ in combination: cytotoxic and radiosensitizing properties in hypoxic mammalian cells.

Authors:  M Astor; E J Hall
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

6.  Peripheral electrophysiological parameters in mice treated with misonidazole.

Authors:  R Von Burg; P J Conroy; W Passalacqua
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

7.  Quantitative cytochemical assessment of the neurotoxicity of misonidazole in the mouse.

Authors:  C Clarke; K B Dawson; P W Sheldon
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.